2023
Integrating neuropsychological research on autism and psychosis to improve clinical outcomes
Schalbroeck R, Foss-Feig J, Jutla A, Ziermans T. Integrating neuropsychological research on autism and psychosis to improve clinical outcomes. Nature Reviews Psychology 2023, 2: 723-739. DOI: 10.1038/s44159-023-00251-3.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersSpectrum disorderSymptoms of autismCo-occurring symptomsCognitive functioningNeuropsychological researchSensory processingNeuropsychological featuresSocial interactionAutismBody of literatureResearch road mapDirect effortsQuality of lifePsychosisDisordersClinical outcomesTreatment optionsCritical questionsFunctioningClinical phenotypeRelevant outcomesResearchSymptomsDepressionFirst-episode psychosis and autism spectrum disorder: a scoping review and a guide to overcome diagnostic challenges
Ferrara M, Curtarello E, Simonelli G, Yoviene Sykes L, Fusar-Poli L, Folesani F, Belvederi Murri M, Aguglia E, Politi P, Grassi L. First-episode psychosis and autism spectrum disorder: a scoping review and a guide to overcome diagnostic challenges. International Journal Of Mental Health 2023, 53: 4-35. DOI: 10.1080/00207411.2023.2276872.Peer-Reviewed Original ResearchFirst-episode psychosisDifferential diagnosisFEP servicesDiagnostic challengeAutism spectrum disorderAdequate differential diagnosisUndiagnosed autism spectrum disorderComprehensive literature searchPRISMA-ScR guidelinesAdult patientsClinical presentationFunctional recoveryHigh prevalenceSpectrum disorderHigh riskPsychotic symptomsComorbid diagnosesSymptoms of autismSuicidal behaviorLiterature searchDiagnosisSymptomsSensory processingPerceptual abnormalitiesSeparate groups
2022
Exploring communicative competence in autistic children who are minimally verbal: The Low Verbal Investigatory Survey for Autism (LVIS)
Naples A, Tenenbaum E, Jones R, Righi G, Sheinkopf S, Eigsti I. Exploring communicative competence in autistic children who are minimally verbal: The Low Verbal Investigatory Survey for Autism (LVIS). Autism 2022, 27: 1391-1406. PMID: 36373838, PMCID: PMC10183057, DOI: 10.1177/13623613221136657.Peer-Reviewed Original ResearchConceptsVerbal autistic childrenAutistic childrenCommunication skillsMeasures of languageParent-report measuresChildren's communication skillsSymptoms of autismLack of wordsVerbal childrenAutism symptomatologyCognitive abilitiesLanguage abilityCommunicative abilitiesVerbal languageCommunicative competenceHelpful interventionsAlternative formsLanguageAutismChildrenClinical implicationsWordsSkillsCommunicationAbility
2006
Autism spectrum disorder in the second year: stability and change in syndrome expression
Chawarska K, Klin A, Paul R, Volkmar F. Autism spectrum disorder in the second year: stability and change in syndrome expression. Journal Of Child Psychology And Psychiatry 2006, 48: 128-138. PMID: 17300551, DOI: 10.1111/j.1469-7610.2006.01685.x.Peer-Reviewed Original ResearchConceptsAutism spectrum disorderSymptoms of ASDAutism Diagnostic Observation Schedule-GenericSyndrome expressionSpectrum disorderParental reportsAcquisition of languageAutism Diagnostic InterviewSymptoms of autismPervasive developmental disorderDyadic social behaviorASD symptomsPDD-NOSSocial dysfunctionSocial behaviorAutismLanguage characteristicsDevelopmental disordersDiagnostic InterviewDiagnostic classificationYoung childrenADOSStereotyped behaviorSecond yearArt diagnostic methods
2000
Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone
McDougle C, Scahill L, McCracken J, Aman M, Tierney E, Arnold L, Freeman B, Martin A, McGough J, Cronin P, Posey D, Riddle M, Ritz L, Swiezy N, Vitiello B, Volkmar F, Votolato N, Walson P. Research Units on Pediatric Psychopharmacology (Rupp) Autism Network Background and Rationale for an Initial Controlled Study of Risperidone. Child And Adolescent Psychiatric Clinics Of North America 2000, 9: 201-224. PMID: 10674197, DOI: 10.1016/s1056-4993(18)30142-1.Peer-Reviewed Original ResearchConceptsOpen-label trialDA neuronal systemsSafety of risperidoneStudy of RisperidonePlacebo-controlled studyUse of risperidoneExtrapyramidal side effectsTarget of pharmacotherapyTreatment of childrenImpaired social behaviorLong-term effectivenessPreclinical evidenceReceptor blockadeTypical antipsychoticsControlled StudyFirst drugPathophysiology of autismLower riskShort-term benefitsSide effectsRisperidonePotent effectsSymptoms of autismNeuronal systemsEnhanced efficacy
1996
A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder
McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L. A Double-blind, Placebo-Controlled Study of Fluvoxamine in Adults With Autistic Disorder. JAMA Psychiatry 1996, 53: 1001-1008. PMID: 8911223, DOI: 10.1001/archpsyc.1996.01830110037005.Peer-Reviewed Original ResearchConceptsStudy of FluvoxamineAutistic disorderSelective serotonin uptake inhibitorAdverse cardiovascular eventsPlacebo-controlled trialWeeks of treatmentSerotonin uptake inhibitorSerotonin neurotransmitter systemShort-term treatmentCardiovascular eventsPlacebo groupMild sedationNeurotransmitter systemsTreatment responseSafe drugUptake inhibitorFluvoxamineSymptoms of autismFluvoxamine maleateDisordersPlaceboAutistic behaviorPatientsAdultsSymptoms
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply